Myriad Genetics Inc (MYGN)

MYGN (NASDAQ:Diversified Services) EQUITY
$20.66
pos +0.03
+0.15%
Today's Range: 20.50 - 21.14 | MYGN Avg Daily Volume: 1,523,000
Last Update: 08/26/16 - 4:00 PM EDT
Volume: 855,481
YTD Performance: -52.20%
Open: $20.70
Previous Close: $20.63
52 Week Range: $19.10 - $46.24
Oustanding Shares: 69,134,651
Market Cap: 1,455,284,404
6-Month Chart
TheStreet Ratings Grade for MYGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 2 6 6 6
Moderate Buy 0 0 0 0
Hold 8 5 6 6
Moderate Sell 1 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 3.02 2.33 2.38 2.38
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 12.31
Price Earnings Comparisons:
MYGN Sector Avg. S&P 500
12.31 12.30 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-41.04% -37.43% -25.71%
GROWTH 12 Mo 3 Yr CAGR
Revenue 4.20 0.20 0.07
Net Income 56.20 -0.10 -0.05
EPS 58.30 0.00 -0.01
Earnings for MYGN:
EBITDA 0.19B
Revenue 0.75B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (06/17) FY (06/18)
Average Estimate $0.26 $0.28 $1.06 $1.23
Number of Analysts 8 6 9 9
High Estimate $0.28 $0.29 $1.15 $1.45
Low Estimate $0.25 $0.27 $0.93 $1.03
Prior Year $0.41 $0.45 $1.63 $1.06
Growth Rate (Year over Year) -36.28% -38.52% -34.83% 15.90%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bruce Kamich

 | Aug 11, 2016 | 2:01 PM EDT
All the long-term indicators are aligned for declines.
By

James "Rev Shark" DePorre

 | Aug 10, 2016 | 10:36 AM EDT
I'm not inclined to make market calls, but the action on my screen is pushing me to a defensive stance.

bearishMyriad downgraded at Barclays

Aug 10, 2016 | 7:45 AM EDT
MYGN was downgraded from Overweight to Equal-weight, Barclays said. $24 price target. Company is losing market share faster than expected.

bearishMyriad downgraded at Piper

Aug 10, 2016 | 7:23 AM EDT
MYGN was downgraded from Overweight to Neutral, Piper Jaffray said. $22 price target. Company is losing market share in hereditary cancer.

bearishMyriad Genetics downgraded at BofA/Merrill

Jul 29, 2016 | 7:52 AM EDT
MYGN was downgraded from Neutral to Underperform, Bank of America/Merrill Lynch said. $25 price target. Pricing pressures will begin to erode earnings growth.
By

Timothy Collins

 | Aug 31, 2015 | 10:37 AM EDT

The stock still maintains a bullish slant on the daily chart.

bullishMyriad upgraded at Wells

Aug 25, 2015 | 7:11 AM EDT

MYGN was upgraded from Market Perform to Outperform, Wells Fargo said. Recent meeting with management confirms a better business outlook. 

bearishMyriad downgraded at Credit Suisse

Feb 4, 2015 | 7:51 AM EST

MYGN was downgraded from Neutral to Underperform, Credit Suisse said. $30 price target. Estimates also cut, given the company's new guidance. 

bullishMyriad upgraded at JMP

Feb 4, 2015 | 7:40 AM EST

MYGN was upgraded from Market Perform to Outperform, JMP Securities said. $50 price target. Stock is attractive, following a 15% decline. 

By

Robert Moreno

 | Oct 2, 2014 | 2:17 PM EDT

Charting setups in Myriad Genetics, Clovis Oncology and Aegerion Pharma.

FIBOCALL: The SPX-cash after Ms. Yellen speaks. The "markets" actually moved today after ...
Finally going to hear the latest views of Yellen today and the market and investor have la...
The BLS revised second quarter 20-16 GDP lower by 0.1% to 1.1%. This should provide adequ...
We have followed all areas of the Healthcare industry for decades. And while there are lik...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.